Skip to content
Screener

Amgen AMGN KYPROLIS — Total revenues

Other product segments

Repatha
$3.02B—
Other products
$1.7B+23.0%
Prolia
$759M-32.4%
EVENITY
$714M+37.8%
ENBREL
$580M-4.0%
TEPEZZA
$576M+14.1%
Otezla
$491M-20.6%
TEZSPIRE
$486M+42.1%
BLINCYTO
$472M+22.9%
Nplate
$430M+16.5%
KRYSTEXXA
$400M+14.6%
Aranesp
$352M-1.9%
XGEVA
$352M-33.8%
Vectibix
$338M+10.8%
UPLIZNA
$335M+90.3%
IMDELLTRA/IMDYLLTRA
$288M+115%

Similar metrics at other companies

Sonida Senior Living logo
SNDAResident revenue — Total revenues
$108.43M+36.8%
Asset Entities logo
ASSTOther revenue — Total revenues
$43K+514%
ALN
ALNYRoyalty revenue — Total revenues
$71.67M+79.3%
Hyatt Hotels logo
HContra revenue — Total revenues
-$17M-13.3%
FTAI Aviation Ltd. logo
FTAIMaintenance revenue — Total revenues
$30.6M-38.3%
FTAI Aviation Ltd. logo
FTAIOther revenue — Total revenues
$6.21M+19,923%

Other financials

Income statement

See full
Revenue$10.1B+9.5%
Gross profit$7.2B+17.4%
Operating income$3.5B+32.3%
Net income$2.4B+65.9%
EPS (diluted)$4.37+64.9%

Balance sheet

See full
Cash & equivalents$574.0M+5.9%
Total debt$57.3B+2.0%
Total equity$11.7B+57.4%
Total assets$95.6B+8.8%

Cash flow

See full
Operating cash flow$4.0B+75.5%
CapEx$513.0M+39.0%
Free cash flow$3.5B+82.6%

Valuation

See full
Market cap$220.64B+44.0%
Enterprise value$277.37B+32.8%
P/E25.2×+2.1×
P/S5.8×+1.4×

Profitability

See full
Gross margin69.5%+5.0pp
Operating margin30%+6.5pp
Net margin23%+4.0pp
FCF margin26.7%-3.7pp

Returns & leverage

See full
Return on equity91.5%-7.7pp
Debt / equity4.9×-2.7×
Current ratio1.4×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Amgen’s 10-Q, filed August 5, 2026.

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000318154-26-000126
Line itemThree months ended June 30, 2026 / U.S.Three months ended June 30, 2026 / ROWThree months ended June 30, 2026 / TotalThree months ended June 30, 2025 / U.S.Three months ended June 30, 2025 / ROWThree months ended June 30, 2025 / Total
XGEVA187165352347185532
Aranesp94258352107252359
KRYSTEXXA3991400349—349
KYPROLIS201113314232146378
Vectibix167171338144161305
UPLIZNA3171833513244176
IMDELLTRA/IMDYLLTRA2335528810727134
Other products(2)1,2834141,6979903901,380

Item 1. FINANCIAL STATEMENTS

FAQ

What is Amgen's KYPROLIS — total revenues?
Amgen (AMGN) reported KYPROLIS — total revenues of $314M in Q2 2026.
How has Amgen's KYPROLIS — total revenues changed year-over-year?
Amgen's KYPROLIS — total revenues decreased by 16.9% year-over-year, from $378M to $314M.
What is the long-term trend for Amgen's KYPROLIS — total revenues?
Over 4 years (2021 to 2025), Amgen's KYPROLIS — total revenues has grown at a 6.2% compound annual growth rate (CAGR), from $1.11B to $1.41B.
What does KYPROLIS — total revenues mean?
This metric represents the total global net sales generated from the commercialization of the proteasome inhibitor therapeutic indicated for the treatment of multiple myeloma. It reflects the market adoption, pricing power, and clinical demand for this specific oncology asset within the company's broader hematology-oncology portfolio. Monitoring this revenue stream provides insight into the competitive positioning of the drug against alternative therapies and the impact of lifecycle management strategies.

Ask your AI about Amgen's kyprolis — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude